Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Other Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has reported Other Accumulated Expenses over the past 7 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Other Accumulated Expenses at $1.2 million for Q1 2026, up 14.34% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (up 14.34% YoY), and the annual figure for FY2025 was $759000.0, up 2.43%.
  • Other Accumulated Expenses reached $1.2 million in Q1 2026 per EWTX's latest filing, up from $759000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.2 million in Q1 2026 and bottomed at $399000.0 in Q4 2023.
  • Median Other Accumulated Expenses over the past 5 years was $804000.0 (2022), compared with a mean of $830529.4.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 235.77% in 2022 before it tumbled 62.29% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $1.1 million in 2022, then plummeted by 62.29% to $399000.0 in 2023, then surged by 85.71% to $741000.0 in 2024, then increased by 2.43% to $759000.0 in 2025, then soared by 56.52% to $1.2 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for EWTX at $1.2 million in Q1 2026, $759000.0 in Q4 2025, and $714000.0 in Q3 2025.